Tipping Points and Endogenous Determinants of Nigrostriatal Degeneration by MPTP

Trends in Pharmacological Sciences

Volumn 38, Issue 6, 2017, Pages 541-555

  Schildknecht, Stefan ^a   Di Monte, Donato A ^b   Pape, Regina ^a   Tieu, Kim ^c   Leist, Marcel ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

astrocytes; autoxidation; MPDP+; MPP+; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CALCIUM ION; CYTOCHROME P450; DOPAMINE TRANSPORTER; ORGANIC CATION TRANSPORTER 3; REACTIVE OXYGEN METABOLITE; VESICULAR MONOAMINE TRANSPORTER 2;

ASTROCYTE; BRAIN DEPTH STIMULATION; BRAIN TISSUE; CALCIUM CELL LEVEL; CELL DEATH; ENERGY EXPENDITURE; HOMEOSTASIS; HUMAN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION; ANIMAL; CHEMICALLY INDUCED; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; INTOXICATION; METABOLISM; NEOSTRIATUM; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ASTROCYTES; DOPAMINERGIC NEURONS; HUMANS; MPTP POISONING; NEOSTRIATUM; NEURODEGENERATIVE DISEASES;

EID: 85018794797     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.03.010     Document Type: Review

References (106)

1. Langston, J.W., et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983), 979–980.
2. Di Monte, D.A., et al. Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. J. Pharmacol. Exp. Ther. 258 (1991), 594–600.
3. Di Monte, D.A., et al. Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes. Glia 5 (1992), 48–55.
4. Heikkila, R.E., et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984), 467–469.
5. Javitch, J.A., et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 82 (1985), 2173–2177.
6. Ramsay, R.R., Singer, T.P., Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261 (1986), 7585–7587.
7. Schildknecht, S., et al. Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol. Appl. Pharmacol. 241 (2009), 23–35.
8. Scholz, D., et al. Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem. 119 (2011), 957–971.
9. Aguirre, P., et al. The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1. Biometals 25 (2012), 795–803.
10. Pöltl, D., et al. Uncoupling of ATP-depletion and cell death in human dopaminergic neurons. Neurotoxicology 33 (2012), 769–779.
11. Sherer, T.B., et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 100 (2007), 1469–1479.
12. Sherer, T.B., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003), 10756–10764.
13. Przedborski, S., et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12 (1992), 1658–1667.
14. Zhang, J., et al. Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J. Neuropathol. Exp. Neurol. 59 (2000), 53–61.
15. Tanaka, S., et al. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL–1 knockout mice. J. Neuroinflammation, 10, 2013, 143.
16. Mount, M.P., et al. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 27 (2007), 3328–3337.
17. Sriram, K., et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16 (2002), 1474–1476.
18. Qi, X., et al. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J. Cell Sci. 126 (2013), 789–802.
19. Rappold, P.M., et al. Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo. Nat. Commun., 5, 2014, 5244.
20. Santos, D., et al. The impact of mitochondrial fusion and fission modulation in sporadic Parkinson's disease. Mol. Neurobiol. 52 (2015), 573–586.
21. Wang, X., et al. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease. Aging Cell 10 (2011), 807–823.
22. Uchida, S., et al. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. Eur. J. Pharmacol. 747 (2015), 160–165.
23. Hikishima, K., et al. Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model. Neuroscience 300 (2015), 585–592.
24. German, D.C., et al. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5 (1996), 299–312.
25. German, D.C., et al. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32 (1992), 667–676.
26. +. FEBS Lett. 189 (1985), 225–230.
27. Russell, S.M., et al. The vectorial orientation of human monoamine oxidase in the mitochondrial outer membrane. Biochem. J. 181 (1979), 7–14.
28. Vincent, S.R., Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain. Neuroscience 28 (1989), 189–199.
29. Jackson-Lewis, V., et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995), 257–269.
30. Efremova, L., et al. Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism. Br. J. Pharmacol. 172 (2015), 4119–4132.
31. + toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters. Biochim. Biophys. Acta 1404 (1998), 305–313.
32. +. Antioxid. Redox Signal. 23 (2015), 1001–1016.
33. Cui, M., et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 8043–8048.
34. Rappold, P.M., et al. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 20766–27137.
35. Chiba, K., et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120 (1984), 574–578.
36. Korytowski, W., et al. Mechanism of oxidation of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+). Biochem. Biophys. Res. Commun. 144 (1987), 692–698.
37. +, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Med. Chem. 28 (1985), 1432–1436.
38. Mik, E.G., et al. Mitochondrial PO2 measured by delayed fluorescence of endogenous protoporphyrin IX. Nat. Methods 3 (2006), 939–945.
39. Lin, C.J., et al. Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J. Neurochem. 114 (2010), 717–727.
40. +) in mouse brain. Neurotox. Res. 25 (2014), 135–145.
41. Grimsby, J., et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat. Genet. 17 (1997), 206–210.
42. Uehara, S., et al. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). Drug Metab. Dispos. 43 (2015), 735–742.
43. Bajpai, P., et al. Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease. J. Biol. Chem. 288 (2013), 4436–4451.
44. Lu, Y., et al. CYP2D6*4 allele polymorphism increases the risk of Parkinson's disease: evidence from meta-analysis. PLoS One, 8, 2013, e84413.
45. Elbaz, A., et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann. Neurol. 55 (2004), 430–434.
46. Ingelman-Sundberg, M., Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5 (2005), 6–13.
47. Herraiz, T., et al. Metabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro-β-carboline by oxidative enzymes. Biomed. Res. Int., 2013, 2013, 248608.
48. Herraiz, T., et al. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol. Appl. Pharmacol. 216 (2006), 387–398.
49. Corsini, G.U., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur. J. Pharmacol. 119 (1985), 127–128.
50. Mann, A., Tyndale, R.F., Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Eur. J. Neurosci. 31 (2010), 1185–1193.
51. Chiba, K., et al. Effects of N-methylmercaptoimidazole on the disposition of MPTP and its metabolites in mice. Eur. J. Pharmacol. 180 (1990), 59–67.
52. + in relation to catecholamine depletion after the oral or subcutaneous administration of MPTP to mice. Life Sci. 45 (1989), 2077–2083.
53. Masoud, S.T., et al. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol. Dis. 74 (2015), 66–75.
54. Lohr, K.M., et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 9977–9982.
55. Gainetdinov, R.R., et al. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70 (1998), 1973–1978.
56. German, C.L., et al. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. Pharmacol. Rev. 67 (2015), 1005–1024.
57. Taylor, T.N., et al. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76 (2014), 97–105.
58. Brighina, L., et al. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. Neurobiol. Aging, 34, 2013, 1712.
59. Yang, X., et al. Polymorphism in the vesicular monoamine transporter 2 gene decreases the risk of Parkinson's disease in Han Chinese men. Parkinsons Dis., 2015, 2015, 903164.
60. Richardson, J.R., et al. Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB J. 20 (2006), 1695–1697.
61. Surmeier, D.J., Schumacker, P.T., Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J. Biol. Chem. 288 (2013), 10736–10741.
62. Chen, T., et al. Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease. Cell Signal. 25 (2013), 2863–2870.
63. Dopeso-Reyes, I.G., Calbindin content and differential vulnerability of midbrain efferent dopaminergic neurons in macaques. Front. Neuroanat., 8, 2014, 146.
64. Yuan, H.H., et al. The neuroprotective effect of overexpression of calbindin-D(28k) in an animal model of Parkinson's disease. Mol. Neurobiol. 47 (2013), 117–122.
65. Hurley, M.J., et al. Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 136 (2013), 2077–2097.
66. 2+ conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. 466 (1993), 727–747.
67. Guzman, J.N., et al. Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29 (2009), 11011–11019.
68. Braak, H., et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 (2004), 121–134.
69. Stevens, D.R., Haas, H.L., Calcium-dependent prepotentials contribute to spontaneous activity in rat tuberomammillary neurons. J. Physiol. 493 (1996), 747–754.
70. 2+ channels regulates locus coeruleus pacemaking. Mol. Cell. Neurosci. 68 (2015), 293–302.
71. Pignatelli, A., et al. Functional properties of dopaminergic neurones in the mouse olfactory bulb. J. Physiol. 564 (2005), 501–514.
72. Khaliq, Z.M., Bean, B.P., Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J. Neurosci. 30 (2010), 7401–7413.
73. Surmeier, D.J., et al. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 198 (2011), 221–231.
74. Chan, C.S., et al. ‘Rejuvenation’ protects neurons in mouse models of Parkinson's disease. Nature 447 (2007), 1081–1086.
75. Ilijic, E., et al. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol. Dis. 43 (2011), 364–371.
76. Gudala, K., et al. Reduced risk of Parkinson's disease in users of calcium channel blockers: a meta-analysis. Int. J. Chronic Dis., 2015, 2015, 697404.
77. Lang, Y., et al. Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis. Pharmacoepidemiol. Drug Saf. 24 (2015), 559–566.
78. Bolam, J.P., Pissadaki, E.K., Living on the edge with too many mouths to feed: why dopamine neurons die. Mov. Disord. 27 (2012), 1478–1483.
79. Matsuda, W., et al. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 29 (2009), 444–453.
80. Nair-Roberts, R.G., Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience 152 (2008), 1024–1031.
81. Brichta, L., Greengard, P., Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update. Front. Neuroanat., 8, 2014, 152.
82. Hardman, C.D., et al. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J. Comp. Neurol. 445 (2002), 238–255.
83. Pissadaki, E.K., Bolam, J.P., The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci., 7, 2013, 13.
84. Harris, J.J., et al. Synaptic energy use and supply. Neuron 75 (2012), 762–777.
85. Goedert, M., et al. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 140 (2017), 266–278.
86. Goedert, M., et al. The synucleinopathies: twenty years on. J. Parkinsons Dis. 7 (2017), S53–S71.
87. Braak, H., Del Tredici, K., Neuropathological staging of brain pathology in sporadic Parkinson's disease: separating the wheat from the chaff. J. Parkinsons Dis. 7 (2017), S73–S87.
88. Schildknecht, S., et al. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J. Neurochem. 125 (2013), 491–511.
89. Vila, M., et al. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74 (2000), 721–729.
90. Purisai, M.G., et al. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol. Dis. 20 (2005), 898–906.
91. Ulusoy, A., et al. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol. Med. 5 (2013), 1119–1127.
92. Helwig, M., et al. Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice. Brain 139 (2016), 856–870.
93. Zharikov, A.D., et al. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J. Clin. Invest. 125 (2015), 2721–2735.
94. Dauer, W., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99 (2015), 14524–14529.
95. Song, L.K., et al. Targeted overexpression of α-synuclein by rAAV2/1 vectors induces progressive nigrostriatal degeneration and increases vulnerability to MPTP in mouse. PLoS One, 10, 2015, e0131281.
96. Taguchi, K., et al. Brain region-dependent differential expression of alpha-synuclein. J. Comp. Neurol. 524 (2016), 1236–1258.
97. Oueslati, A., et al. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183 (2010), 115–145.
98. McCormack, A.L., et al. Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J. Neuropathol. Exp. Neurol. 67 (2008), 793–802.
99. Mosharov, E.V., et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62 (2009), 218–229.
100. Jackson-Lewis, V., Przedborski, S., The MPTP mouse model of Parkinson's disease: the true, the false, and the unknown. Nass, R., Przedborski, S., (eds.) Parkinson's Disease: Molecular and Therapeutic Insights from Model Systems, 2008, Elsevier, 147–158.
101. Lotharius, J., et al. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277 (2002), 38884–38894.
102. Martinez-Vicente, M., Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118 (2008), 777–788.
103. Bové, J., Perier, C., Neurotoxin-based models of Parkinson's disease. Neuroscience 211 (2012), 51–76.
104. Jackson-Lewis, V., Przedborski, S., Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007), 141–151.
105. Villeneuve, D.L., Adverse outcome pathway (AOP) development I: strategies and principles. Toxicol. Sci. 142 (2014), 312–320.
106. Ockleford, C., et al. Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia. EFSA J., 15, 2017, 4691.